Emyria (ASX:EMD) Short-Term Debt: A$0.06 Mil (As of Dec. 2025)


What is Emyria Short-Term Debt?

Emyria ASX:EMD -5.00% Short-Term Debt is A$0.06 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Emyria's Short-Term Debt for the quarter that ended in Dec. 2025 was A$0.06 Mil.

Emyria's quarterly Short-Term Debt declined from Dec. 2024 (A$0.17 Mil) to Jun. 2025 (A$0.00 Mil) but then increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.06 Mil).

Emyria's annual Short-Term Debt declined from Jun. 2023 (A$0.91 Mil) to Jun. 2024 (A$0.81 Mil) and declined from Jun. 2024 (A$0.81 Mil) to Jun. 2025 (A$0.00 Mil).

Emyria Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Emyria Short-Term Debt Related Terms

Emyria Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Emyria's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emyria Short-Term Debt Chart

Emyria Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.91 0.81 0.00

Emyria Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 0.81 0.17 0.00 0.06
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.06 Mil mean?
Emyria (ASX:EMD) has a Short-Term Debt of A$0.06 Mil as of Dec. 2025.
Is Emyria's Short-Term Debt too high?
Emyria's current Short-Term Debt is A$0.06 Mil.
How does Emyria's Short-Term Debt compare to VEEV and BTSG?
Emyria's Short-Term Debt of A$0.06 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Healthcare Providers & Services company?
A good Short-Term Debt depends on the Healthcare Providers & Services industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Emyria's current Short-Term Debt is A$0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 26.7% above its estimated fair value. The current Short-Term Debt is A$0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Short-Term Debt is A$0.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emyria Business Description

Other Exchanges Q84:Germany
Address D2, 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.